

SARS-CoV-2

antigen-detecting rapid diagnostic tests

AN IMPLEMENTATION GUIDE




World Health
Organization

FIND 
Because diagnosis matters

SARS-CoV-2

antigen-detecting
rapid diagnostic tests

AN IMPLEMENTATION GUIDE



World Health
Organization

FIND 
Because diagnosis matters

SARS-CoV-2 antigen-detecting rapid diagnostic tests: an implementation guide

ISBN 978-92-4-001774-0 (electronic version)

ISBN 978-92-4-001775-7 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. SARS-CoV-2 antigen-detecting rapid diagnostic tests: an implementation guide. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

ACKNOWLEDGMENTS	iv
ABBREVIATIONS	v
1. OVERVIEW OF IMPLEMENTATION GUIDE	8
2. CONTEXT OF THE CORONAVIRUS DISEASE (COVID-19) PANDEMIC	10
Brief history of the pandemic	11
Central role of testing in the response	11
Urgent needs in the pandemic response	11
3. HOW COVID-19 IS DIAGNOSED	12
Molecular testing	13
Rapid diagnostic testing	13
4. ROLE OF AG-RDTs AS PART OF A COVID-19 DIAGNOSTIC TESTING STRATEGY	16
Recommendations for the use of SARS-CoV-2 Ag-RDTs	17
5. HOW SARS-CoV-2 AG-RDTs WORK	21
Structure of Ag-RDTs	22
Interpreting Ag-RDT performance	22
Ag-RDT performance expectations and characteristics	24
6. KEY IMPLEMENTATION CONSIDERATIONS	25
Integrating a SARS-CoV-2 Ag-RDT testing strategy into the national response plan	27
RDT procurement: selecting the right product	29
RDT supply chain management and logistics	31
Training	33
QA processes	34
Data management and connectivity	36
M&E	38
Communication and community engagement	41
REFERENCES	42
ANNEX: COUNTRY READINESS CHECKLIST FOR SARS-CoV-2 AG-RDT IMPLEMENTATION	43
Download the file here	

Acknowledgments

This SARS-CoV-2 antigen-detecting rapid diagnostic test implementation guide is a product of collaboration between the World Health Organization (WHO) and the Foundation for Innovative New Diagnostics (FIND), with support from the Access to COVID-19 Tools (ACT) Accelerator Country Preparedness Working Group; African Society for Laboratory Medicine (ASLM); Centers for Disease Control and Prevention (CDC); Clinton Health Access Initiative (CHAI); The Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund); Médecins Sans Frontières; and PATH.

We acknowledge the assistance of many people in the development of this guide, including (in alphabetical order):

- Core contributors: Heidi Albert (FIND); Julianne Birungi (UNICEF); Alexandre Costa (UNICEF); Jane Cunningham (WHO); Owen Demke (CHAI); Arika Garg (CHAI); Emma Hannay (FIND); Hellen Kassa (FIND); Paolo Maggiore (CHAI); Naureen Naqvi (UNICEF); Christopher Oxenford (WHO); Chase Perfect (Coalition Plus); Fifi Rahman (Unitaid); André Trollip (FIND).
- Reviewers: Michael Aidoo (CDC); Priyanka Bajaj (PATH); Céline Barnadas (WHO); Eileen Burke (Global Fund); Fatim Cham-Jallow (Global Fund); Sébastien Cognat (WHO); Kara Durski (WHO); Laurence Flevaud (Médecins Sans Frontières); Nancy Gerloff (CDC); Lionel Gresh (PAHO/WHO); Martine Guillermin (Global Fund); Shilpi Jain (CDC); Rigveda Kadam (FIND); Praveen Kandasamy Sugendran (PATH); Laura Kerr (UNICEF); Shaukat Khan (CHAI); Lesley McGee (CDC); Deepak More (PATH); Pascale Ondoa (ASLM); Mark Perkins (WHO); Vincent Petit (UNICEF); Analía Porras (PAHO); Purnima Ranawat (CHAI); Maria Rioja (CHAI); Jilian Sacks (FIND); Katrina Sleeman (CDC); Shibu Vijayan (PATH).
- Lead writers and editors: Talya Underwood (writer, Anthos Communications); Fiona Stewart (editor).

Abbreviations

Ab	antibody
Ab-RDT	antibody-detecting rapid diagnostic test
Ag	antigen
Ag-RDT	antigen-detecting rapid diagnostic test
COVID-19	coronavirus disease 19
EUL	emergency use listing
HIS	health information system
LIMS/LIS	laboratory information management system
LMIC	low- and middle-income country
M&E	monitoring and evaluation
NAAT	nucleic acid amplification test
NPV	negative predictive value
PPE	personal protective equipment
PPV	positive predictive value
PT	proficiency testing
QA	quality assurance
QC	quality control
rRT-PCR	real-time reverse transcription polymerase chain reaction
RDT	rapid diagnostic test
SARS-CoV-2	severe acute respiratory syndrome coronavirus 2



1

OVERVIEW OF IMPLEMENTATION GUIDE



预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24185

